Pharmaceutical Interventions in the Management of Oral Mucositis in Cancer Patients Undergoing Dental Treatments: A Randomized Controlled Trial

Abstract

Benzydamine hydrochloride, chlorhexidine as mouthwash, amifostine, palifermin, and a placebo were the five treatments that were investigated in this study. Oral mucositis is a common adverse effect of cancer treatment, and this study aimed to analyse and compare the effectiveness of these treatments. For the purpose of evaluating the treatments, we used descriptive statistics, analysis of variance (ANOVA), and rigorous tests to determine whether or not the means were equal. We took into account standard scores, deviations from the mean, and statistically significant differences. The data showed significant differences in the mean scores of each treatment group (p 0.001), indicating that different treatments had different levels of effectiveness in treating oral mucositis. Benzydamine hydrochloride consistently had superior mean scores and lower standard deviations compared to chlorine dioxide mouthwash, amifostine, palifermin, and the placebo. Oral mucositis may be treated with a variety of different medications, however the research suggests that benzydamine hydrochloride in is the most successful option. These results have significant ramifications for the decisions that should be made for therapy based on evidence, and they highlight the need to compare the relative efficacy of the many drugs used to treat oral mucositis. Additional research is required to examine the underlying mechanisms and unique treatment responses, which will pave the way for more individualised and effective treatment approaches.